Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients.
OBJECTIVE
The purpose of the study was to determine whether ovarian cancer patients have activated lymphocytes as indicated by the presence of soluble interleukin-2 receptor-alpha and to compare soluble interleukin-2 receptor-alpha with other markers in ovarian cancer.


METHODS
Ascites and serum from patients with advanced active ovarian cancer was tested for the presence of elevated levels of soluble interleukin-2 receptor-alpha and compared with normal controls. Levels of soluble interleukin-2 receptor-alpha were also compared with levels of CA 125 and macrophage colony-stimulating factor in the same patients, to evaluate the correlation between different markers.


RESULTS
Elevated levels of soluble interleukin-2 receptor-alpha were detected in 86 of 86 (100%) ascites samples and 67 of 85 (79%) serum samples from patients with advanced epithelial ovarian cancer. In contrast, only 12 of 25 (48%) benign ascites samples and one of 88 (1%) serum samples from controls had elevated levels. There was no obvious correlation between levels of soluble interleukin-2 receptor-alpha and levels of CA 125; however, levels of soluble interleukin-2 receptor-alpha did correlate with levels of macrophage colony-stimulating factor. Concurrent measurement of serum-soluble interleukin-2 alpha and CA 125 levels detected 100% of patients with epithelial ovarian cancer.


CONCLUSIONS
The detection of elevated levels of soluble interleukin-2 receptor-alpha in serum and ascites indicates the presence of activated lymphocytes in patients with epithelial ovarian cancer. Ascites and serum levels of soluble interleukin-2 receptor-alpha are elevated in patients with advanced ovarian cancer and warrant assessment as a potential complementary marker to CA 125 for early detection of ovarian cancer and management of patients with advanced ovarian cancer.
Hurteau
J A
JA
Toronto General Hospital, Ontario, Canada.
Simon
H U
HU
Kurman
C
C
Rubin
L
L
Mills
G B
GB
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis / Q000097:blood; D001202:Ascitic Fluid / Q000276:immunology*; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood*; D001769:Blood / Q000276:immunology; D002277:Carcinoma / Q000175:diagnosis / Q000276:immunology*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D007963:Leukocytes, Mononuclear; D016014:Linear Models; D008969:Molecular Sequence Data; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D013601:T-Lymphocytes
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2